Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mipomersen dosing regimens in hypercholesterolemia
NCT00216463Phase 2Completed
- Sponsor
- Kastle Therapeutics LLC
- Start
- Aug 2005
- Primary completion
- Mar 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of mipomersen in hypercholesterolemia, sponsored by Kastle Therapeutics LLC. Started Aug 2005; status: completed.
02
Drugs
mipomersen
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00216463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216463.